Disciplined Equity Management Inc. Raises Stock Holdings in Pfizer Inc. $PFE

Disciplined Equity Management Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 19.6% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 87,050 shares of the biopharmaceutical company’s stock after acquiring an additional 14,290 shares during the period. Pfizer makes up approximately 1.2% of Disciplined Equity Management Inc.’s holdings, making the stock its 12th biggest position. Disciplined Equity Management Inc.’s holdings in Pfizer were worth $2,110,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter valued at $27,000. North Capital Inc. bought a new stake in shares of Pfizer in the first quarter worth $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the first quarter valued at $28,000. Horizon Financial Services LLC bought a new position in Pfizer in the first quarter valued at about $35,000. Finally, WPG Advisers LLC purchased a new position in Pfizer in the first quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.53 on Wednesday. The company has a market capitalization of $139.44 billion, a P/E ratio of 13.05, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.82. The firm’s 50 day simple moving average is $24.88 and its two-hundred day simple moving average is $24.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the prior year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.